Management of thrombocytopenia with ENHERTU

Thrombocytopenia can occur in patients treated with ENHERTU.1

  • Of the 257 patients with unresectable or metastatic HER2+ breast cancer who received ENHERTU 5.4 mg/kg in DESTINY-Breast03, the incidence of platelet count decrease2
    • Grade 1 incidence 13.2%; Grade 2 incidence 5.1%; Grade 3 incidence 6.2%; Grade 4 incidence 1.2%
  • Based on the severity of thrombocytopenia, manage through treatment interruption or dose reduction.1 See below for dose modifications

Dose modifications for thrombocytopenia1

Severity Treatment modification
Grade 3
(platelets less than
50 to 25 x 109/L)
  • Interrupt ENHERTU until resolved to Grade 1 or less, then maintain dose
Grade 4
(platelets less than
25 x 109/L)

Toxicity grades are in accordance with NCI-CTCAE v.5.0.

Get ENHERTU Resources for You and Your Practice

An ENHERTU resource guide summarizing the efficacy and safety, dosing and administration, and recommendations for managing adverse reactions
Ready to learn more about ENHERTU?
HER2, human epidermal growth factor receptor 2; NCI-CTCAE, National Cancer Institute–Common Terminology Criteria for Adverse Events.